October 14, 2008 - CoreValve said the expanded clinical evaluation of its ReValving System for percutaneous aortic valve replacement (PAVR) in high-risk patients with aortic stenosis continues to enroll patients at an accelerating pace.
More than 1,800 patients have now been treated worldwide at nearly 100 centers in 20 countries.
